Scammers

Well... at long last Cassava Sciences (SAVA) reported out the data in its first PIII trial. Not even close. As I type, the share is down 86%. Since it has no other compounds, that I'm aware of, the company is toast. What's particularly devious, just a week ago they hired a commercial officer, thus pumping the share.

The second trial is shut down.

What started out as a pain compound company, morphed into an Alzheimer's outfit on the basis of a compound with a fantastical MoA. Many in the scientific community called it out as garbage over the years, but relying on gullible retail plungers, kept the momentum going for more than a decade based on vapour. Quite a trick. Now, the turkeys have come home to roost. And a boatload of retail plungers won't be moving into their villas in France and St. Kitts.

There is a legion of nano- and micro- cap pharmas out there promising that they've found the answer, where Big Pharma has failed. Seldom happens, and when it has, it's because the nano-cap has developed a robust platform tech over many years, not just a single molecule. Caveat emptor.